Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2010

View Archived Issues

Actelion Pharma discloses new orexin receptor antagonists

Achaogen describes new tobramycin derivatives

Tetraphase Pharmaceuticals claims new antibacterial compounds

Amplyx Pharmaceuticals divulges novel HIV protease inhibitors

Repligen receives grant to support RG-3039 program for spinal muscular atrophy

New ICAM-1/VCAM-1-targeting nanocarriers developed for ocular neovascularization therapies

Simvastatin may stabilize visual field in normal-tension glaucoma

Recordati and Nymox sign licensing agreement for NX-1207 in BPH

Bayer HealthCare submits European application for new YAZ-based oral contraceptive regimen

EMA recommends approval of Xiapex for treatment of Dupuytren's contracture

FDA clears phase Ia trial of NSI-189 for treatment of depression

FDA clears phase I trial of respiratory syncytial virus vaccine RSV-F

Amarin provides update on phase III ANCHOR trial

Anacor begins phase III AN-2690 trial in onychomycosis

FDA issues complete response letter to AstraZeneca for Brilinta

Merck KGaA and sanofi-aventis to jointly investigate new anticancer agents

MM-302 shows promise to treat HER2-overexpressing tumors

Genentech provides update on Avastin for metastatic breast cancer

CK-2017357 leads to functional improvement in ALS

Repros Therapeutics provides update on low-dose Proellex trial

Novel Toll-like receptor 7 agonists discovered

Children's Hospital Boston begins mecasermin trial in Rett's syndrome

Canadian researchers identify new methyl sulfanyl pyrmidines

Amira Pharma nominates preclinical candidate in LPA-related program

Enzon and NCI begin phase I trials of EZN-2968 and EZN-2208

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...